Surgery has played an important role in treating non-small cell lung cancer (NSCLC). Resection is usually the first choice for NSCLC patients in stage Ⅰ and stage Ⅱ, and it is also an important part of the comprehensive treatment for the stage ⅢA patients. Standard surgery of NSCLC includes resection of the primary tumor lesion and swee-ping of ipsilateral lymph nodes and mediastinal lymph nodes. The goal of treatment for lung cancer in early stage aims to decrease the rate of recurrence and mortality. In recent years, video-assisted thoracoscopic surgery and da Vinci robotic minimal invasive surgery have made gratifying achievements, especially for small peripheral lung nodules surgery. For patients with NSCLC at stage ⅢA, the central focus of research is about identifying patients who will benefit in the surgery combining with chemotherapy and radiotherapy, therefore to choose the appropriate surgery.
Objective To evaluate the safety and advantage in lymph node dissection of Ivor-Lewis esophagectomy in patients with esophageal cancer. Methods Clinical and pathological data of 78 patients with esophageal cancer who underwent Ivor-Lewis esophagectomy between September 2012 and March 2014 were collected and analyzed. Another 86 esophageal cancer patients who underwent esophagectomy of Sweet procedure during the same period were regarded as the controls. Duration of surgery, intra-operative blood loss, incidence of main complications and positive rate of lymph node were compared between the two groups. Results The duration of surgery in Ivor-Lewis group [(254.5±38.4) minutes] was longer than that in the Sweet group [(216.7±31.3) minutes]; and the average intra-operative blood loss in Ivor-Lewis group [(165.5±40.3) mL] was higher than that in the Sweet group [(148.7±35.4) mL]; the differences were significant (P < 0.01). Incidence of hoarseness in Ivor-Lewis group was significantly higher than that in Sweet group (P < 0.05), while incidences of other comp lications between the two groups were similar (P > 0.05). The proportion of patients with positive lymph nodes in Ivor-Lewis group (60.3%, 47/78) was significantly higher than that in Sweet group (26.7%, 23/86) (P < 0.05). Average number of lymph nodes dissected in Ivor-Lewis group (21.5±5.3) was significantly higher than that in Sweet group (10.6±4.1). Lymph nodes along the right recurrent laryngeal nerve was the most common metastasis in patients of Ivor-Lewis group, while lymph nodes in that area in Sweet group patients could hardly be dissected. Conclusions Ivor-Lewis esophagectomy is a safe surgical procedure for esophageal cancer. Ivor-Lewis procedure has more advantages in lymph node dissection than Sweet procedure.
ObjectiveTo explore influence of different nutritional approaches on liver function in patients after esophagectomy. MethodsA total of 160 patients with esophageal cancer who underwent surgical treatment were divided into a enteral nutrition (EN) group and a total parenteral nutrition (TPN) group according to different medical staff. There were 80 patients in each group. Two and 7 days postoperatively, albumin (ALB), prealbumin (PA), alanine aminotransferase (ALT) and total bilirubin (TB) of the 2 groups were examined to evaluate liver function. ResultsAbnormities in liver function (ALB, PA, ALT, TB) was common phenomenon in esophageal cancer patients, but there was no statistical difference in ALB, PA, ALT, TB on the 2nd postoperative day between the EN group and the TPN group (P > 0.05). On the 7th postoperative day, liver functions were improved than those on the 2nd postoperative day in the two groups. And frequencies of liver function abnormity in the EN group were significantly lower than those in the TNP group (P < 0.05). ConclusionCompared with TPN, EN has advantages in facilitating hepatic protein synthesis and recovery of liver function after esophagectomy.
Objective To explore the tumor suppressive effect of superantigen staphylococcal enterotoxin B (SEB) for mice beared by Lewis lung cancer cell (LLCC). Methods SEB gene expressive plasmid PCDH-SEB-GFP was constructed and transfected into LLCC and it was detected by Western blot. Tumor-bearing mice model was established by subcutaneous injection of LLCC and SEB expressive plasmid PCDH-SEB-GFP was successfully injected into the tumor to observe its suppressive effect on the growth of Lewis lung cancer in mice. Results SEB expression was detected after transfection of LLCC with SEB gene plasmid PCDH-SEB-GFP. Intratumoral injection of plasmid PCDH-SEB-GFP could significantly inhibit the growth of Lewis lung cancer in tumor-bearing mice. Conclusions Intratumoral injection of superantigen SEB expressive plasmid can inhibit the growth of Lewis lung cancer in mice. It deserves a further study that SEB gene can work as an exogenous antigen gene in immune gene therapy for lung cancer.
ObjectiveTo construct tumor specific tubercle bacillus antigen Ag85A gene lentiviral vector driven by murine telomerase catalytic subunit promoter (PmTERT), paving the way for further research in tumor targeting immuno-gene therapy. MethodsPmTERT was amplified by PCR method, with murine genomic DNA as template. Then, transcriptional activities of PmTERT in various murine and human cell strains were studied by luciferase assay. Ag85A expression lentiviral vectors driven by cytomegalo virus (CMV) promoter and PmTERT respectively (pLVX-Ag85ACMV and pLVX-Ag85A-PmTERT) were constructed with nucleic acid cloning approach. And above recombinants were verified with DNA sequencing and Western blot. ResultsLucifease assay revealed that 331 bp PmTERT cloned in present research had transcriptional activity in murine Lewis lung cancer cells, human lung adenocarcinoma cells A549, and human esophageal cancer cells EC-109, while no transcriptional activity in murine fibroblasts NIH3T3 and human embryo fibroblasts MRC-5. Western blot revealed expression of Ag85A in pLVX-Ag85A-CMV transfected Lewis and NIH3T3 cells, pLVX-Ag85A-PmTERT transfected Lewis cells, no expression in pLVX-Ag85A-PmTERT transfected NIH3T3 cells. ConclusionPmTERT has tumor specific transcriptional activity. Ag85A gene can express selectively in tumor cells, driven by PmTERT.
ObjectiveTo study microRNA (miRNA) involved in the regulation of sinus cell differentiation by comparing sinus node, atrial myocardium, and ventricular myocardium specific miRNA expression profile differences in Kunming mice. MethodsA total of 180 Kunming mice, aged 60-90 days and weighing 35-45 g, were selected without gender differences after the method of anatomical localization for sinus node had been confirmed by preliminary experiments in another 10 Kunming mice. All the sinus node, atrial myocardium, and ventricular myocardium tissue from 180 mice were dissected and frozen by liquid nitrogen. The structure of tissue was observed by HE staining. Total RNA were extracted and quality-controlled before hybridize with miRNA chip. The chips with miRNA were used to screen specific miRNAs; and correlation analysis of gene function was done. ResultsThe area of mice sinus node located at juncture of the superior vena cava and the right atrium junction with crista as its longitudinal axis, ranged 2.0 mm×1.5 mm×1.0 mm. HE staining showed the sinus cells were less, with no stripes, lightly stained cytoplasm, large and round nucleus, and there were much fibrous connective tissue around cells with a visible sinus node artery. The miRNA microarray results showed that compared with atrial myocardium and ventricular myocardium, there were 39 differentially expressed miRNAs in sinus node, including 12 up-regulated miRNAs and 27 down-regulated miRNAs. Based on the regulatory networks of differential miRNA and target gene, the regulatory miRNA was obtained. ConclusionThe differentially expressed miRNA in mice sinus node possibly may be involved in the regulation of sinus cell differentiation.